CV: hypotension, ARRHYTHMIAS, ECG changes.
Derm: photosensitivity.
EENT: blurred vision, dry eyes.
Endo: gynecomastia.
GI: constipation, dry mouth, nausea, paralytic ileus.
GU: ↓libido, urinary retention.
Hemat: blood dyscrasias.
Metab: weight gain.
Neuro: drowsiness, fatigue, agitation, confusion, hallucinations, insomnia, SUICIDAL THOUGHTS.
Major Depressive Disorder
- PO (Adults): 25–50 mg 3–4 times daily (not to exceed 300 mg/day); total daily dose may be given at bedtime.
- PO (Geriatric Patients): 25 mg at bedtime initially, up to 100 mg/day in divided doses.
- PO (Children >12 yr): 25–50 mg/day in divided doses (not to exceed 100 mg/day).
- PO (Children 6–12 yr): 10–30 mg/day in 2 divided doses.
Enuresis
- PO (Children
6 yr): 25 mg once daily 1 hr before bedtime; ↑ if necessary by 25 mg at weekly intervals to 50 mg in children <12 yr, up to 75 mg in children >12 yr.
Therapeutic Classification: antidepressants
Pharmacologic Classification: tricyclic antidepressants
Absorption: Well absorbed from the GI tract.
Distribution: Widely distributed to tissues.
Protein Binding: 89–95%.
Metabolism/Excretion: Mostly metabolized by the liver (CYP2D6 isoenzyme) to desipramine;the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly ↑ imipramine concentrations and an ↑ risk of adverse effects.
Half-life: 8–16 hr.